

SATURDAY, 4 MAY

08:30	Opening/Keynote	Rami Burstein
Education Sessions		
09:00	Session 1: Migraine Management: Guidelines and Patient Preferences	Cristina Tassorelli
09:05	Guidelines for Acute and Preventive Management of Migraine <ul style="list-style-type: none"> • Overview of current guidelines • Differences in the approach for acute vs. preventive management • Recommendations and evidence supporting the guidelines 	Simona Sacco
09:25	Oral vs. Injectable: Patient Preferences and Clinical Implications <ul style="list-style-type: none"> • Overview of oral (gepants) vs. injectable (mAbs) treatments • Data on patient preferences and reasons behind them • Clinical implications of these preferences, including adherence and efficacy 	Cristina Tassorelli
09:45	Treatment Duration: Gepants vs. mAbs <ul style="list-style-type: none"> • Recommended treatment duration for both drug classes • Clinical evidence supporting these recommendations 	Bianca Raffaelli
10:05	Discussion and Q&A Session	
10:35	AM Coffee Break	
11:05	Session 2: Evaluating and Modifying Migraine Treatment	Patricia Pozo-Rosich
11:10	When to Evaluate: 3-Month vs. 6-Month Milestones <ul style="list-style-type: none"> • Pros and cons of both evaluation points • Clinical studies supporting each timeline • Recommendations for different patient profiles 	Piero Barbanti
11:35	Switching Protocols: Transitioning Between mAbs <ul style="list-style-type: none"> • Reasons for considering a switch between different mAbs • Clinical guidelines for making the switch • Patient case studies or scenarios to demonstrate the process 	Patricia Pozo-Rosich
12:00	The Road Ahead: Future Perspective on Migraine Treatment <ul style="list-style-type: none"> • Brief overview of emerging treatments • Potential changes or updates to current guidelines • Encouraging an individualized approach to treatment 	Roberto de Icco
12:15	Discussion and Q&A Session	
12:45	Lunch Satellite Symposium	
Science Sessions		
Session 3: Diverse Mechanisms of Action as a Scientific Rationale for Combination Therapy		
14:00	Triptans Plus Gepants in Acute Treatment and Gepants/mAbs Plus OnabotulinumtoxinA in Prophylactic Treatment	Rami Burstein
14:20	The Anti-PACAP Pathway and its Potential in Combination With Anti-CGRP Pathway Therapy	Messoud Ashina
14:40	Moderated Discussion	
Session 4: Early Intervention During the Prodromal Phase Should Be a Standard Practice in the Treatment of Acute Migraine Attacks: A Debate		
15:00	For	Richard Lipton
15:20	Against	Hakan Ashina
15:40	Moderated Discussion	
16:00	PM Coffee Break	
Session 5: Why Specific Treatments for Cluster Headache Remain Challenging to Develop		
16:30	The Problem of Elusive Pathophysiology	Rolf Fronczek
16:50	The Way Forward	Peter J Goadsby
17:10	Moderated Discussion	
17:30	Reception: An Evening with the Experts	

SUNDAY, 5 MAY

Public Policy Sessions		
08:00	AI and Machine Learning in Headache Management	Erling Tronvik
08:20	Global Disparities in Migraine Care: A Call for Universal Access to Diagnosis and Treatment	Mario Peres
08:40	Global Burden of Disease (GBD) Study: Challenges and Opportunities in Headache Disorders	Andreas Husøy
09:00	Strategic Approaches to Overcome Policy-Driven Barriers in Accessing Migraine Treatments	Aynur Özge
Brainstorming Sessions		
09:20	Proper Methods for Conducting Research on Headaches at the Population Level	Tobias Kurth
09:50	Migraine Frequency as a Driver of Treatment: Is There a Neurobiological Basis?	Arne May
10:20	Sexual Hormones are Key to Migraine Pathophysiology: Why Do We Lack Specific Approaches?	Gisela Terwindt
10:35	Coffee Break	
11:05	The Future of Headache Medicine: A Discussion	
12:10	Closing Remarks	Rami Burstein

